Tamoxifen Tales

Suggestions for Scientific Survival

1st Edition - January 12, 2022

Author: V. Craig Jordan

Paperback ISBN:

9 7 8 - 0 - 3 2 3 - 9 9 6 1 7 - 4

Hardback ISBN:

9 7 8 - 0 - 3 2 3 - 8 5 0 5 1 - 3

eBook ISBN:

9 7 8 - 0 - 3 2 3 - 8 5 9 7 2 - 1

Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons learned that are applicable to the next generation of scientists. This book provides a manual on the successful mentoring of young scientists, including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan’s 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women’s healthcare around the world.

Additionally, it illustrates the versatility of a scientist with a commitment to serving societies. This important resource will be a useful and interesting book for established medical scientists, research mentors and advanced students wanting to chart a successful and impactful research career.

Cover image
Title page
Table of Contents
Copyright
Dedication
Dedication
Dedication
About the author
Acknowledgments
The scope and foundation steps in a career
Foreword—Melvyn Bragg
None
Why write this book?
Number 1: “Have a dream” (mine was to develop a drug, any drug, to treat cancer)
Number 5: “Be the most enthusiastic person you know” (I am a bit too enthusiastic for most people)
Number 8: “Them that stick it out are them that win” (I never stop trying)
Number 9: “That little bit extra” (My life's philosophy is total commitment to achieve the goal)
Prelude
Chapter 1. Beginnings
Going to America
My early years in Cheshire
Growing up in Bramhall
Chapter 2. Leeds University: foundation of a career
Postscript on Career Preparation for a Degree in Pharmacy from the Department of Pharmacology at Leeds
Chapter 3. The chance to be a Ph.D. student at the University of Leeds
Chapter 4. Two antiestrogenic strategies to treat breast cancer at the Worcester Foundation
Breakthrough
Postscript
Chapter 5. A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds
Chemoprevention
The move to adjuvant therapy
Unanticipated sadness and success of Alderley Park
An investigation of the molecular mechanism of action of tamoxifen
A time of major decisions
Chapter 6. Tamoxifen's patenting problems in America, which created a “cancer treatment company”
Chapter 7. Two opportunities on different continents
Chapter 8. The good, the bad and the ugly of tamoxifen at Wisconsin
Animal models—finding the bad about tamoxifen
Linking tamoxifen with endometrial cancer
Chapter 9. “Sliding Doors” and serendipity
Chapter 10. South to Northwestern in Chicago
The research plan to build a new Tamoxifen team at the Robert H. Lurie Cancer Center
Educational outreach and research priorities at the Robert H. Lurie Comprehensive Cancer Center
Deciphering the molecular mechanism of antiestrogen action and the new science of estrogen-induced apoptosis
Extensive animal models of estrogen-induced apoptosis to decipher pathways and clinical utility
Consolidating the financial flow with federal grants
Celebrations around the Diana, Princess of Wales Professorship in Cancer Research
A surprise honor
The glamor of the “Big Three of Cancer Research”: Bristol Myers Squibb Award (2001), American Cancer Society Medal of Honor (2002), and the Charles F. Kettering Prize (clinical) from General Motors (2003): a triumph for the Robert H. Lurie Comprehensive Cancer Center at its zenith
Conclusion
Chapter 11. Forward to the Fox Chase Cancer Center in Philadelphia
The Fox Chase Cancer Center Tamoxifen Team
Peer recognition at Fox Chase Cancer Center for the accomplishments of the Tamoxifen Teams
Chapter 12. Get out and go to Georgetown
Building my Tamoxifen Team at Georgetown
The Peacock Café, Georgetown
Graduate students at Georgetown
Chapter 13. Closing the circle on Tamoxifen Tales
Chapter 14. “If I wanted to buy your brain, what would that cost?”: rebirth at M.D. Anderson Cancer Center
Ping Fan completes our molecular mechanism to explain the increase in breast cancers in the CEE/MPA treated women 10 years after menopause in the WHI
Philipp Maximov, Balkees Abderrahman, and Ramona Curpan define the molecular mechanism of action of the partial estrogen agonist bisphenol to delay apoptosis
Balkees Abderrahman and Ramona Curpan define the molecular mechanism of action of the clinically relevant estrogen mimic TTC-352
Battle with the “enemy within” 4 years later
Recognition from national academies and major international awards that acknowledge a change in medicine while at the MD Anderson Cancer Center
Recognition from professional academic societies
Recognition, honorary appointments or honorary degrees, etc
Chapter 15. “Invest in the young”
Chapter 16. Scientific survival suggestions
Chapter 17. An account of students obtaining a Ph.D. degree (or an MD for physicians in the British System) while in the Tamoxifen Team over the last 50 years
Clive J. Dix, Department of Pharmacology, University of Leeds, 1976–79; ICI Pharmaceuticals Division Research Scholar
Anna T. Riegel (Neé Tate), McArdle Laboratory for Cancer Research, University of Wisconsin, 1980–83; Fulbright Hays Scholar
Stewart D. Lyman, McArdle Laboratory, University of Wisconsin, 1982–84
Ethel M. Cormier, Molecular and Cellular Biology Graduate Program, University of Wisconsin, 1982–88
Marco M. Gottardis, Department of Human Oncology, University of Wisconsin, 1983–89
Catherine S. Murphy, Department of Human Oncology, University of Wisconsin, 1984–90
Meei-Huey Jeng, Department of Human Oncology, University of Wisconsin, 1987–92
Shun-Yuan Jiang, Department of Human Oncology, University of Wisconsin, 1987–92; Scholarship from the Taiwanese Ministry of Defense
Doug M. Wolf, Department of Human Oncology, University of Wisconsin, 1988–93; Susan G. Komen graduate student
John J. Pink, Department of Human Oncology, University of Wisconsin, 1990–95
William H. Catherino, Department of Human Oncology, University of Wisconsin, MD/Ph.D. program, 1991–95
Jennifer I. MacGregor-Schafer, Northwestern University, Department of Defense Graduate Student Training Program, Chicago, IL, 1995–2001
Ruth M. O'Regan, University College, Dublin, Ireland, 1996–2000 (Faculty in Medical Oncology, Northwestern University, Chicago, IL)
Rita C. Dardes, Department of Obstetrics and Gynecology, University of Sao Paulo, Brazil, 1998–2001
Philipp Y. Maximov, N.I. Pirogov Russian National Medical Research University, Russia, 2006–10
Ifeyinwa Obiorah, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2010–14
Elizabeth Sweeney, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2011–14
Balkees Abderrahman, Department of Breast Medical Oncology, University of Texas, MD, Anderson Cancer Center/University of Leeds, split site model C applicants of very high quality (inaugural candidate) 2017–20
Chapter 18. Case studies: in their own words
Clive James Dix, Ph.D.
Anna Riegel, Ph.D.
Marco Gottardis, Ph.D.
Andreas Friedl, MD
Doug Wolf, Ph.D.
Shun-Yuan Jiang, Ph.D.
William H. Catherino, MD, Ph.D.
Anait S Levenson, MD, Ph.D.
Debra A. Tonetti, Ph.D.
Rita Dardes, MD, Ph.D.
Clodia Osipo, Ph.D.
Ruth O'Regan, MD
David Bentrem, MD
Joan Lewis-Wambi, Ph.D.
Philipp Y. Maximov, MD, Ph.D., MBA
Ping Fan, MD, Ph.D.
Balkees Abderrahman MD, Ph.D.
Index